Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,739 stopped studies mapped to Lymphoma and descendants · 89% state a reason
Over the 1,739 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05276622 | Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)(PaCE-MM) | — | terminated | Mar 11, 2022 | UNC Lineberger Comprehensive Cancer Center | Investigator left the institution. | Investigator |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent…(CHRONOS-4) | Phase 3 | terminated | Dec 10, 2015 | Bayer | Company decided to terminate this study due to study did not meet the primary endpoint. | Sponsor / business decision |
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)(PANAMA) | Phase 1 | terminated | Mar 8, 2016 | Karyopharm Therapeutics Inc | sponsor decision | Sponsor / business decision |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT03890289 | Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma(GAUDEALIS) | Phase 2 | terminated | Mar 26, 2019 | Fondazione Italiana Linfomi - ETS | Study was halted prematurely due to safety, since tocity stopping rules have been met | Safety / toxicity |
| NCT03648372 | A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System | Phase 1 / Phase 2 | terminated | Aug 27, 2018 | Takeda | Enrolment Challenges | Enrollment / accrual |
| NCT06050512 | Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | Phase 1 / Phase 2 | withdrawn | Sep 22, 2023 | Kathleen Dorritie | Closure of trial per BMS | Other (stated, no rule matched) |
| NCT03804424 | 64Cu-LLP2A for Imaging Multiple Myeloma | Early Phase 1 | terminated | Jan 15, 2019 | Washington University School of Medicine | Drug formulation changed, opening new trial | Other (stated, no rule matched) |
| NCT05113342 | Descartes-25 in Relapsed/Refractory Multiple Myeloma | Phase 1 | terminated | Nov 9, 2021 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated. | Enrollment / accrual |
| NCT06003179 | Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With…(LOKI) | Phase 1 | withdrawn | Aug 21, 2023 | University Health Network, Toronto | recruitment challenges and sites who initially expressed interest declined. | Enrollment / accrual |
| NCT04745832 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL… | Phase 3 | terminated | Feb 9, 2021 | MEI Pharma, Inc. | Discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT05882305 | KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial | Early Phase 1 | withdrawn | May 31, 2023 | Kousai Bio Co., Ltd. | No Participants Enrolled | Enrollment / accrual |
| NCT03870451 | Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma | N/A | terminated | Mar 12, 2019 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT05289492 | Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Mar 21, 2022 | iTeos Therapeutics | Company operational decision. Decision to stop study is not due to safety or efficacy concerns | Safety / toxicity |
| NCT03311126 | Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle… | Phase 2 | terminated | Oct 16, 2017 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT03417765 | Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas | Phase 1 / Phase 2 | withdrawn | Jan 31, 2018 | GlyPharma Therapeutics | Business decision | Sponsor / business decision |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell… | Phase 1 / Phase 2 | terminated | Apr 24, 2020 | Genmab | Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on… | Safety / toxicity |
| NCT05134740 | (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).(pediTACTAL) | Phase 1 | withdrawn | Nov 26, 2021 | Baylor College of Medicine | Leadership determination | Other (stated, no rule matched) |
| NCT04860466 | A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory… | Phase 1 | terminated | Apr 27, 2021 | Celgene | Business objectives have changed. | Sponsor / business decision |
| NCT05521178 | Cardiotoxicities in Patients Receiving BTKi | — | withdrawn | Aug 30, 2022 | Dana-Farber Cancer Institute | Funding for study was withdrawn | Funding |
| NCT03710915 | A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma | Phase 1 | terminated | Oct 18, 2018 | HitGen Inc. | Company decision | Sponsor / business decision |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and… | Phase 2 | terminated | Jul 5, 2017 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT04271930 | Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes | N/A | terminated | Feb 17, 2020 | Medical College of Wisconsin | This study terminated early due to lack of participant retention | Other (stated, no rule matched) |
| NCT03220347 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of… | Phase 1 | terminated | Jul 18, 2017 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT04816526 | Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma… | Phase 2 | terminated | Mar 25, 2021 | Cartesian Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT05315713 | An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of… | Phase 1 / Phase 2 | terminated | Apr 7, 2022 | Hoffmann-La Roche | Study was terminated due to Sponsor decision. | Sponsor / business decision |
| NCT02298816 | B-Cell Hematologic Malignancy Vaccination Registry(HMvax-Regist) | — | withdrawn | Nov 24, 2014 | Wake Forest University Health Sciences | No patients enrolled | Enrollment / accrual |
| NCT05971056 | Providing Cancer Care Closer to Home for Patients With Multiple Myeloma | N/A | terminated | Aug 2, 2023 | Washington University School of Medicine | Insufficient funding | Funding |
| NCT06625359 | High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by… | Phase 2 | terminated | Oct 3, 2024 | Seoul National University Hospital | slow enrollment | Enrollment / accrual |
| NCT04431635 | Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in… | Phase 1 | terminated | Jun 16, 2020 | University of Michigan Rogel Cancer Center | Loss of study funding | Funding |
| NCT02099539 | QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Mar 31, 2014 | Altor BioScience | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT02509039 | A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With… | Phase 1 | terminated | Jul 27, 2015 | Celgene | Replaced it with another clinical trial. | Other (stated, no rule matched) |
| NCT03136497 | A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory… | Phase 1 | terminated | May 2, 2017 | Hackensack Meridian Health | Lack of enrollment | Enrollment / accrual |
| NCT02002598 | Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma | Phase 1 / Phase 2 | terminated | Dec 6, 2013 | Suzanne Lentzsch, MD | Slow accrual and loss of funding | Enrollment / accrual |
| NCT04659044 | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment… | Phase 2 | terminated | Dec 9, 2020 | Academic and Community Cancer Research United | Trial closed due to low accrual rate | Enrollment / accrual |
| NCT05094206 | CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies | Phase 1 | terminated | Oct 26, 2021 | Medical College of Wisconsin | Treated four patients: 2 at a dose of 1x10\^6 cells/kg and 2 ad at dose of 2.5x10\^6 cells/kg. All… | Other (stated, no rule matched) |
| NCT02978235 | A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple… | Phase 1 | terminated | Nov 30, 2016 | Taiho Oncology, Inc. | The trial was put on Clinical Hold and subsequently terminated prior to Phase 2 due to cases of… | Other (stated, no rule matched) |
| NCT03000634 | 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation… | Phase 2 | withdrawn | Dec 22, 2016 | University of Arkansas | Study was not and will not be initiated due to lack of funding. | Funding |
| NCT03530683 | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801),… | Phase 1 | terminated | May 21, 2018 | Pfizer | A business decision was made by Pfizer to terminate the study. Termination was not due to any… | Safety / toxicity |
| NCT04036461 | A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and… | Phase 1 | terminated | Jul 29, 2019 | Celgene | Slow accrual | Enrollment / accrual |
| NCT05219513 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904… | Phase 1 | terminated | Feb 2, 2022 | Hoffmann-La Roche | The study was terminated due to sponsor portfolio re-alignment. | Sponsor / business decision |
| NCT01998035 | Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | Phase 1 / Phase 2 | terminated | Nov 28, 2013 | Columbia University | PI left institution | Investigator |
| NCT03743246 | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With… | Phase 1 / Phase 2 | terminated | Nov 16, 2018 | Celgene | Absence of significant therapeutic benefit over existing therapies | Other (stated, no rule matched) |
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or… | Phase 1 / Phase 2 | terminated | Dec 19, 2020 | Emory University | Lack of funding | Funding |
| NCT01843868 | Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP | N/A | withdrawn | May 1, 2013 | Australasian Leukaemia and Lymphoma Group | Study halted prematurely, prior to enrollment of first participant due to protracted logistical and… | Enrollment / accrual |
| NCT02091063 | ACY-1215 for Relapsed/Refractory Lymphoid Malignancies | Phase 1 / Phase 2 | terminated | Mar 19, 2014 | Jennifer Amengual | Lack of funding | Funding |
| NCT00848601 | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and… | Phase 1 | terminated | Feb 20, 2009 | Astex Pharmaceuticals, Inc. | The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in… | Safety / toxicity |
| NCT04852822 | Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic… | — | terminated | Apr 21, 2021 | University of Washington | The study ended earlier than anticipated due to slow accrual. | Enrollment / accrual |
| NCT04545333 | The clonoSEQ® Watch Registry | — | terminated | Sep 11, 2020 | Adaptive Biotechnologies | Sufficient data collected. | Other (stated, no rule matched) |
| NCT05908396 | Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | terminated | Jun 18, 2023 | IGM Biosciences, Inc. | Company Decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Dec 12, 2024source: clinicaltrials